Preptin, another peptide product of the pancreatic β-cell, is osteogenic in vitro and in vivo

American Journal of Physiology - Endocrinology and Metabolism

Volumn 292, Issue 1, 2007, Pages

  Cornish, J ^a   Callon, K E ^a   Bava, U ^a   Watson, M ^a   Xu, X ^a   Lin, J M ^a   Chan, V A ^a   Grey, A B ^a   Naot, D ^a   Buchanan, C M ^b   Cooper, G J S ^a,b   Reid, I R ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Bone anabolic; Bone active hormone; Osteoblast

Indexed keywords

AMYLIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; PEPTIDE HORMONE; PEPTIDE PREPTIN; THYMIDINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; BONE DEVELOPMENT; BONE GROWTH; CELL COUNT; CELL LINEAGE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DNA SYNTHESIS; DRUG EFFECT; DRUG SYNTHESIS; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HORMONE ACTION; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; OSTEOBLAST; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RAT;

ANIMALS; BONE DEVELOPMENT; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; HUMANS; INSULIN-LIKE GROWTH FACTOR II; INSULIN-SECRETING CELLS; MALE; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; OSTEOBLASTS; OSTEOCLASTS; OSTEOGENESIS; PEPTIDE FRAGMENTS; PEPTIDES; PERTUSSIS TOXIN; RATS; RECEPTORS, PEPTIDE; SWISS 3T3 CELLS;

EID: 33845975599     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00642.2005     Document Type: Article

References (25)

1. Amling M, Takeda S, Karsenty G. A neuro (endo)crine regulation of bone remodeling. Bioessays 22: 970-975, 2000.
2. Bell GI, Merryweather JP, Sanchez-Pescador R, Stempien MM, Priestley L, Scott J, Rall LB. Sequence of a cDNA clone encoding human preproinsulin-like growth factor II. Nature 310: 775-777, 1984.
3. Bollag RJ, Zhong Q, Ding KH, Phillips P, Zhong L, Qin F, Cranford J, Mulloy AL, Cameron R, Isales CM. Glucose-dependent insulinotropic peptide is an integrative hormone with osteotropic effects. Mol Cell Endocrinol 177: 35-41, 2001.
4. Buchanan CM, Phillips AR, Cooper GJ. Preptin derived from proinsulin-like growth factor II (proIGF-II) is secreted from pancreatic islet beta-cells and enhances insulin secretion. Biochem J 360: 431-439, 2001.
5. Cooper GJ, Willis AC, Clark A, Turner RC, Sim RB, Reid KB. Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci USA 84: 8628-8632, 1987.
6. Cornish J, Callon KE, Reid IR. Insulin increases histomorphometric indices of bone formation In vivo. Calcif Tissue Int 59: 492-495, 1996.
7. Cornish J, Callon KE, Cooper GJ, Reid IR. Amylin stimulates osteoblast proliferation and increases mineralized bone volume in adult mice. Biochem Biophys Res Commun 207: 133-139, 1995.
8. Cornish J, Callon KE, King AR, Cooper GJ, Reid IR. Systemic administration of amylin increases bone mass, linear growth, and adiposity in adult male mice. Am J Physiol Endocrinol Metab 275: E694-E699, 1998.
9. Cornish J, Callon KE, Bava U, Kamona SA, Cooper GJ, Reid IR. Effects of calcitonin, amylin, and calcitonin gene-related peptide on osteoclast development. Bone 29: 162-168, 2001.
10. Cornish J, Callon KE, Lin CQ, Xiao CL, Gamble GD, Cooper GJ, Reid IR. Comparison of the effects of calcitonin gene-related peptide and amylin on osteoblasts. J Bone Miner Res 14: 1302-1309, 1999.
11. Cornish J, Callon KE, Lin CQ, Xiao CL, Mulvey TB, Coy DH, Cooper GJ, Reid IR. Dissociation of the effects of amylin on osteoblast proliferation and bone resorption. Am J Physiol Endocrinol Metab 274: E827-E833, 1998.
12. Cornish J, Grey A, Callon KE, Naot D, Hill BL, Lin CQ, Balchin LM, Reid IR. Shared pathways of osteoblast mitogenesis induced by amylin, adrenomedullin, and IGF-1. Biochem Biophys Res Commun 318: 240-246, 2004.
13. Cornish J, Callon KE, Naot D, Palmano KP, Banovic T, Bava U, Watson M, Lin J M, Tong PC, Chen Q, Chan VA, Reid HE, Fazzalari N, Baker HM, Baker EN, Haggarty NW, Grey AB, Reid IR. Lactoferrin is a potent regulator of bone cell activity and increases bone formation in vivo. Endocrinology 145: 4366-4374, 2004.
14. Ducy P, Amling M, Takeda S, Priemel M, Schilling AF, Beil FT, Shen J, Vinson C, Rueger JM, Karsenty G. Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass. Cell 100: 197-207, 2000.
15. Gowan LK, Hampton B, Hill DJ, Schlueter RJ, Perdue JF. Purification and characterization of a unique high molecular weight form of insulin-like growth factor II. Endocrinology 121: 449-458, 1987.
16. Grey A, Banovic T, Naot D, Hill B, Callon K, Reid I, Cornish J. Lysophosphatidic acid is an osteoblast mitogen whose proliferative actions involve G(i) proteins and protein kinase C, but not P42/44 mitogen-activated protein kinases. Endocrinology 142: 1098-1106, 2001.
17. Khosla S, Hassoun AA, Baker BK, Liu F, Zein NN, Whyte MP, Reasner CA, Nippoldt TB, Tiegs RD, Hintz RL, Conover CA. Insulin-like growth factor system abnormalities in hepatitis C-associated osteosclerosis. Potential insights into increasing bone mass in adults. J Clin Invest 101: 2165-2173, 1998.
18. Reid IR. Relationships among body mass, its components, and bone. Bone 31: 547-555, 2002.
19. Reid IR. Leptin deficiency - lessons in regional differences in the regulation of bone mass. Bone 34: 369-371, 2004.
20. Reid IR, Baldock PA, Cornish J. Nutrition-related peptides and bone homeostasis. J Bone Miner Res 21: 495-500, 2006.
21. Robinson MJ, Cobb MH. Mitogen-activated protein kinase pathways. Curr Opin Cell Biol 9: 180-186, 1997.
22. Rotwein P. Two insulin-like growth factor I messenger RNAs are expressed in human liver. Proc Natl Acad Sci USA 83: 77-81, 1986.
23. Valenzano KJ, Heath-Monnig E, Tollefsen SE, Lake M, Lobel P. Biophysical and biological properties of naturally occurring high molecular weight insulin-like growth factor II variants. J Biol Chem 272: 4804-4813, 1997.
24. Whyte MP, Teitelbaum SL, Reinus WR. Doubling skeletal mass during adult life: the syndrome of diffuse osteosclerosis after intravenous drug abuse. J Bone Miner Res 11: 554-558, 1996.
25. Xie D, Cheng H, Hamrick M, Zhong Q, Ding KH, Correa D, Williams S, Mulloy A, Bollag W, Bollag RJ, Runner RR, McPherson JC, Insogna K, Isales CM. Glucose-dependent insulinotropic polypeptide receptor knockout mice have altered bone turnover. Bone 37: 759-769, 2005.